Mcl-1 inhibitor 6 |
| Catalog No.GC66017 |
L'inhibiteur Mcl-1 6 est un inhibiteur sélectif de la protéine de la leucémie À cellules myéloÏdes 1 (Mcl-1) actif par voie orale avec un Kd de 0,23 nM et un Ki de 0,02 μM. L'inhibiteur Mcl-1 6 possède une sélectivité supérieure par rapport aux autres membres de la famille Bcl-2 (Bcl-2, Bcl2A1, Bcl-xL et Bcl-w, Kd> 10 μM). L'inhibiteur de Mcl-1 6 est un puissant agent antitumoral.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2598978-56-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Mcl-1 inhibitor 6 is an orally active, selective myeloid cell leukemia 1 (Mcl-1) protein inhibitor with a Kd of 0.23 nM and a Ki of 0.02 μM. Mcl-1 inhibitor 6 possesses superior selectivity over other Bcl-2 family members (Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w, Kd>10 μM). Mcl-1 inhibitor 6 is a potent antitumor agent[1].
Mcl-1 inhibitor 6 has Kis of 10 μM and 1.57μM for Bcl-2 and Bfl-1, respectively[1].
Mcl-1 inhibitor 6 (1, 5 μM; for 48 h) significantly induces apoptosis in a concentration-dependent manner[1].
Mcl-1 inhibitor 6 (0.1, 5 μM; for 4 h) remarkably upregulates PARP cleavage in H929 cells in a concentration-dependent manner[1].
Mcl-1 inhibitor 6 (for 72 h) shows antiproliferative activities against the tumor cell lines (H929, MV4-11, SK-BR-3, NCI-H23; IC50=0.36-3.02 μM). Mcl-1 inhibitor 6 shows ideal selectivity against CML cell line K562 (IC50>30 μM)[1].
Apoptosis Analysis[1]
| Cell Line: | H929 cells |
| Concentration: | 1, 5 μM |
| Incubation Time: | For 48 hours |
| Result: | Significantly induced apoptosis in a concentration-dependent manner. |
Western Blot Analysis[1]
| Cell Line: | H929 cells |
| Concentration: | 0.1, 0.5, 1, 5 μM |
| Incubation Time: | For 4 hours |
| Result: | Remarkably upregulated PARP cleavage in H929 cells in a concentration-dependent manner. |
Mcl-1 inhibitor 6 (compound 40; 60 mg/kg with PO or 20 mg/kg with IP; every two days for 14 days) shows desired in vivo tumor growth inhibition activity[1].
Mcl-1 inhibitor 6 (3 mg/kg with IV or 10 mg/kg with PO) has a T1/2 of 2.3 hours, a CL of 15.18 mL/min•kg by IV[1].
| Animal Model: | Balb/c nude female mice (7 weeks) loaded with MV4-11 xenografts[1] |
| Dosage: | 60 mg/kg (PO) or 20 mg/kg (IP) |
| Administration: | IP or PO; every two days for 14 days |
| Result: | Showed desired in vivo tumor growth inhibition activity (T/C = 37.30% and 5.52% by po and ip administration, respectively). |
| Animal Model: | SD rats (200-250 g)[1] |
| Dosage: | 3 mg/kg (IV) or 10 mg/kg (PO) (Pharmacokinetic Analysis) |
| Administration: | IV or PO |
| Result: | Had a T1/2 of 2.3 hours, a CL of 15.18 mL/min•kg by IV. Had a T1/2 of 2.1 hours, a CL of 36.8 mL/min•kg and a Cmax of 2012.95 ng/mL. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *